Moomoo AI 已提取核心信息
RedHill Biopharma Ltd., a specialty biopharmaceutical company, announced on March 5, 2024, that its investigational drug opaganib has been selected for evaluation by the U.S. government's Chemical Medical Countermeasures (Chem MCM) Program and Chemical Countermeasures Research Program (CCRP) as a potential medical countermeasure against Sulfur Mustard exposure. The evaluation, which includes assessing opaganib's efficacy against sub-chronic fibrosis and acute respiratory distress syndrome (ARDS) resulting from Sulfur Mustard, is managed by the Biomedical Advanced Research and Development Authority (BARDA) and the National Institute of Allergy and Infectious Diseases (NIAID). Opaganib is a novel oral small molecule and the first sphingosine kinase-2 (SPHK2) inhibitor to be considered for this purpose. The drug, which has a five-year shelf-life and is...Show More
RedHill Biopharma Ltd., a specialty biopharmaceutical company, announced on March 5, 2024, that its investigational drug opaganib has been selected for evaluation by the U.S. government's Chemical Medical Countermeasures (Chem MCM) Program and Chemical Countermeasures Research Program (CCRP) as a potential medical countermeasure against Sulfur Mustard exposure. The evaluation, which includes assessing opaganib's efficacy against sub-chronic fibrosis and acute respiratory distress syndrome (ARDS) resulting from Sulfur Mustard, is managed by the Biomedical Advanced Research and Development Authority (BARDA) and the National Institute of Allergy and Infectious Diseases (NIAID). Opaganib is a novel oral small molecule and the first sphingosine kinase-2 (SPHK2) inhibitor to be considered for this purpose. The drug, which has a five-year shelf-life and is easy to administer, is also being developed for other indications such as COVID-19, ARDS, and oncology. The selection of opaganib follows its previous acceptance into the Radiation and Nuclear Countermeasures Program (RNCP) for Acute Radiation Syndrome (ARS), indicating its potential broad activity across different types of injuries. RedHill Biopharma, in collaboration with Apogee Biotechnology Corporation, is working towards FDA approval for opaganib's use against potential chemical weapon attacks.
专业生物制药公司RedHill Biopharma Ltd. 于2024年3月5日宣布，其研究药物奥帕加尼布已被美国政府的化学医学对策（Chem MCM）计划和化学对策研究计划（CCRP）选中进行评估，作为针对硫芥暴露的潜在医疗对策。该评估包括评估奥帕加尼布对亚慢性纤维化和由硫芥引起的急性呼吸窘迫综合征（ARDS）的疗效，由生物医学高级研究与发展局（BARDA）和美国国家过敏和传染病研究所（NIAID）管理。奥帕加尼布是一种新型的口服小分子，也是第一个考虑用于此目的的鞘氨醇激酶2（SPHK2）抑制剂。该药物的保质期为五年，易于服用，还正在开发用于 COVID-19、ARDS 和肿瘤学等其他适应...展开全部
专业生物制药公司RedHill Biopharma Ltd. 于2024年3月5日宣布，其研究药物奥帕加尼布已被美国政府的化学医学对策（Chem MCM）计划和化学对策研究计划（CCRP）选中进行评估，作为针对硫芥暴露的潜在医疗对策。该评估包括评估奥帕加尼布对亚慢性纤维化和由硫芥引起的急性呼吸窘迫综合征（ARDS）的疗效，由生物医学高级研究与发展局（BARDA）和美国国家过敏和传染病研究所（NIAID）管理。奥帕加尼布是一种新型的口服小分子，也是第一个考虑用于此目的的鞘氨醇激酶2（SPHK2）抑制剂。该药物的保质期为五年，易于服用，还正在开发用于 COVID-19、ARDS 和肿瘤学等其他适应症。奥帕加尼布的选择是在其先前被急性辐射综合症（ARS）辐射与核对策计划（RNCP）接受之后选择的，这表明其在不同类型的伤害中可能具有广泛活性。RedHill Biopharma与Apogee Biotechnology Corporation合作，正在努力争取美国食品药品管理局批准使用奥帕加尼布对抗潜在的化学武器攻击。
有用
没用